NUVB
Nuvation BioCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-04
Current thesis
The bull case is that IBTROZI is showing credible early commercial traction, first-line mix is improving, durability data remain strong, and $533.7 million of cash gives Nuvation time to build the launch while advancing safusidenib and other pipeline options [#SEC-8K-2026-05-04].
Posture
Mixed
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-08-06 · BMO.
What can break
Biotech execution risk remains elevated around pivotal-study progress, regulatory timelines, and capital allocation even with a solid current cash balance.
Momentum
89
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $8.50 · Bear $4.00
Earnings
2026-08-06 · BMO
Data freshness
Prices
As of 2026-08-04
Fundamentals
As of 2026-08-04 • Vendor: Data Vendor v1
Scores
As of 2026-08-04 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-08-04
Investment thesis
As of 2026-08-04
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $12.78
Why
Momentum89 · Δ7d +3.7
Value41 · Δ7d +0.1
Sentiment58 · Δ7d +10.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
89
10% active weight
Current posture
7d trendImproving
Δ7d
+3.7
Δ21d
+7.0
Value
41
40% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.0
Sentiment
58
49% active weight
Current posture
7d trendImproving
Δ7d
+10.1
Δ21d
-6.9
Why this grade
Composite grade C. Momentum 88.6 / Value 41.1 / Sentiment 58.3
Fundamentals (TTM)As of 2026-08-04
Fundamentals (TTM)
As of 2026-08-04
Market Cap
$2.25B
Beta
1.53
Shares Out
349.2M
P/E (TTM) · Derived
-10.7
P/S (TTM)
110.10
P/FCF (TTM) · Derived
-17.42
Rev YoY
+2598.7%
EPS YoY
-109.1%
Gross Margin
+89.4%
Op Margin
-871.0%
Net Debt
-$316.45M
Current Ratio
7.44
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology